celularity



THE NEXT **EVOLUTION** IN **CELLULAR MEDICINE**

October 2021

Disclaimer

This presentation has been prepared for use by Celularity, Inc. ("Celularity"). This presentation, and any information disclosed, whether in writing or orally, to you as part of (or otherwise in connection with) this presentation, is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in Celularity, may not be used for any other purpose and may not be reproduced or redistributed, in whole or in part, without the prior written consent of Celularity. Any photocopying, disclosure, reproduction or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Celularity and is not intended to form the basis of any investment decision in Celularity. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in Celularity and the transactions contemplated in this presentation.
This presentation shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Neither the Securities and Exchange Commission (the "SEC") nor any state or territorial securities commission has approved or disapproved of the securities or determined if this presentation is truthful or complete.

Forward-Looking Statements

This presentation contains certain "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding Celularity's expectations, hopes, beliefs, intentions or strategies regarding the future, including, without limitation, statements regarding: (i) the success and timing of Celularity's cellular therapeutic development activities and initiating clinical trials, (ii) the success and timing of Celularity's planned clinical trials, (iii) Celularity's ability to obtain and maintain regulatory approval of any of Celularity's therapeutic candidates, (iv) Celularity's plans to research, discover and develop additional therapeutic candidates, including by leveraging genetic engineering and other technologies and expanding into additional indications, (v) Celularity's ability to expand its manufacturing capabilities, and to manufacture Celularity's therapeutic candidates and scale production, and (vi) Celularity's ability to meet the milestones set forth herein. Any statements contained herein, including any underlying assumptions, that are not statements of historical fact may be deemed to be forward-looking statements and any such projections, statements, forecasts and other information or characterizations of future events or circumstances reflect various estimates and assumptions concerning anticipated results. Forward-looking statements include statements regarding Celularity's future financial position and performance, business strategy, budgets, projected costs, plans, synergies and objectives of management for future operations. Without limiting the foregoing, the words "believes," "anticipates," "continues", "could", "may", "might", "plans," "expects," "intends," "estimated," "forecasted," "projection", "possible", "potential", "predicted", "projected", "should", "strive", "would" and similar expressions used in connection with any discussion of future operating or performance may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements.

No representations or warranties are made by Celularity or any of its affiliates or representatives as to the accuracy of any such projections, modeling, data, targets, statements and other information contained herein. It is understood and agreed that any such projections, models, data, targets, statements and other information are not to be viewed as facts and are subject to significant business, financial, economic, operating, competitive and other risks, uncertainties and contingencies many of which are beyond Celularity's control, that no assurance can be given that any particular financial projections, ranges, or targets will be realized, that actual results may differ from projected results and that such differences may be material.

These forward-looking statements are based on Celularity management's current expectations and beliefs about future events based on information available to them as of the date hereof. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances. Except as required by law, Celularity is not under any obligation to, and expressly disclaims any obligation to, update or alter any forward-looking statements whether as a result of any such changes, new information, subsequent events or otherwise.
Achieving Celularity's business and financial objectives, including growth in operations and maintenance of a strong balance sheet and liquidity position, could be adversely affected by, among other things: (i) the outcome of any legal proceedings that may be instituted against Celularity; (ii) the ability to maintain the listing of the Celularity's securities on Nasdaq; (iii) risks inherent in developing Celularity's therapeutic candidates; (iv) risks associated with Celularity's ongoing and planned clinical trials, such as unexpected data or clinical site activation rates or clinical trial enrollment rates that are lower than expected; (v) difficulties arising from Celularity's third-party licenses, or supply-chain or manufacturing challenges; (vi) Celularity's ability to obtain adequate financing to fund its planned clinical trials and other expenses; and (vii) trends in the industry, changes in the competitive landscape, delays or disruptions due to the COVID-19 pandemic, as well as changes in the legal and regulatory framework for the industry or unexpected litigation or disputes and future expenditures.
Other unknown or unpredictable factors or factors currently considered immaterial also could have an adverse effect on Celularity's results. Consequently, there can be no assurance that the actual results or developments anticipated by Celularity will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Celularity.
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Celularity has not independently verified the accuracy or completeness of any such third-party information. Any data on past performance or modeling contained herein is not an indication as to future performance. Celularity has not assumed any obligation to update the information in this presentation.
Certain information contained in this presentation relates to or is based on studies, publications, surveys and Celularity's own internal estimates and research. Such estimates and research has not been verified by any independent source. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions.
Celularity owns or has the rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply, a relationship with Celularity, or an endorsement or sponsorship by or of Celularity. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this presentation may appear without the TM, SM, ® or © symbols, but such references are not intended to indicate, in any way, that Celularity will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.
This presentation is not intended to form the basis of any investment decision.

CELULARITY'S VISION

To deliver innovative off-the-shelf allogeneic cellular medicines for patients with high unmet need at unparalleled scale, quality and cost.



Lead the evolution in placental-derived therapeutics:
advance the discovery of the placenta as a limitless, renewable source of neonatal cells, which are biologically preferred to cells from adult bone marrow or peripheral blood.

Target large markets with high unmet need:
broad therapeutic application including cancer, infectious, and degenerative diseases.

Develop safe and effective therapies:
leverage inherent advantages of placental-derived cells to produce uniform, scalable and optimized cellular medicines.

Deliver off-the-shelf, affordable therapies:
cryopreserved allogeneic cellular medicines and biomaterial products that clinicians can access on demand and off-the-shelf, enabling repeat dosing/multiple cycles as required in an outpatient setting.

CELULARITY: COMPANY HISTORY

Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation



2000 – Anthrogenesis Corporation – Founded by Dr. Robert Hariri
2002 – Anthrogenesis acquired by Celgene, becomes Celgene Cellular Therapeutics
2005 – Allogeneic Placental Mesenchymal-like Stromal Cells in Crohn's, DFU
2014 – Celgene & Bluebird Bio Autologous CAR-T Collaboration
2015 – Celgene & Juno Therapeutics Autologous CAR-T collaboration
2016 – FIH allogeneic placental-derived NK cell therapy product (Placental NK-007)

KEY: *CORPORATE MILESTONE* *CLINICAL MILESTONE* *FINANCIAL MILESTONE*

CELULARITY PLACENTAL-DERIVED PRODUCT PLATFORM

Capitalizing on the Benefits of Placental-Derived Cells to Target Multiple Diseases



One Placenta → Many Patients

- Universal donor material
- No requirement for matching between a patient and donor



1 Donor

Cryopreserved - On Demand & Off-The-Shelf

- No immunogenicity or toxicity
- Re-dose\fine tune treatments
- Absence of allo-antibodies

Postpartum Placenta

- Abundant, reliable, renewable and biologically consistent raw material
- *Nature's 'professional'* ***universal donor tissue***
- +140 Million Worldwide

Greatest Degree of Natural Stemness

- Greater proliferative performance (Cmax), and persistence
- Greater natural immune tolerance

100-100K Doses/Placenta

- Unparalleled scalability

SINGLE-SOURCE, PLACENTA-BASED PLATFORM DRIVING BROAD PIPELINE

4 Key Cell Types Driving 6 Clinical Indications and Potential for Broad Expansion



MANUFACTURING >> Purpose-built, fully integrated manufacturing facility; rapidly scalable, end-to-end supply chain

FUTURE OPPORTUNITIES AND INDICATIONS

Potential Future CAR Constructs for Oncological Indications

- CD22
- CD123
- BCMA
- GD2
- Her2

- Myelodysplastic Syndrome (MDS)
- Infectious Disease (ID)

Potential Future Monoclonal Antibodies for Combination Oncology Therapies

- Erbitux
- Rituxan
- Daratumumab
- Durvalumab

- ARDS
- Pulmonary Sarcoidosis

MANUFACTURING OVERVIEW

Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translational Research & Biorepository



PURPOSE BUILT FACILITY FOR COMMERCIAL-SCALE CELLULAR THERAPEUTIC MANUFACTURING

- $80M investment in cGMP/cGTP manufacturing
- Enables greater control, efficiency and optimization than is achievable by outsourcing to contract manufacturing organizations (CMOs) alone

STAFFED BY OVER 100 HIGHLY SPECIALIZED SCIENTISTS, ENGINEERS & TECHNICIANS.

- Optimized, product-specific CMC, QA/QC and manufacturing processes accelerate product development, production and commercialization
- Over 2 decades of experience with source material procurement

COMMERCIAL SCALE, GMP-READY

- 9 Grade C/ISO 7 suites
- 6 Grade D/ISO 8 labs
- Dedicated translational research labs

Celularity benefits from Celgene's 20 year+ investment in developing the technologies and capabilities required to manufacture cellular products at scale with consistent and reliable quality

OUR EXPERIENCED LEADERSHIP TEAM

With Deep Expertise in Cell Therapy

Executive Leadership Team

Robert J. Hariri, MD, PhD

Founder, Chairman & CEO

Celgene

Weill Cornell Medicine

Anthrogenesis CORPORATION

Andrew Pecora, MD, FACP, CPE

President

Hackensack Meridian John Theurer Cancer Center

Progenitor Cell Therapy, LLC

John Haines

Chief Operating Officer

ANDISCERN

Penn University of Pennsylvania

IONETIX

David Beers

Chief Financial Officer

Goldman Sachs

T.RowePrice

Bradley Glover, PhD

Chief Technology Officer

Kite Pharma

Roche

Genentech

Anne Jones, PhD

Chief Business Officer

genuity science

Agilent

Amersham Biosciences

GE Healthcare

Beloo Mirakhur, MD, PhD

EVP, Clinical Development

AMGEN

IPSEN Innovation for patient care

gsk

Dr. Stephen Brigido

President, Degenerative Diseases

Geisinger Commonwealth School of Medicine

Keary Dunn, Esq.

EVP & General Counsel

NOVARTIS

SANOFI

PIPELINE
Overview

CELL TYPE	PROGRAM	INDICATION	2021	2022
Unmodified Natural Killer Cell	**CYNK-001** (cryopreserved)	Acute Myeloid Leukemia (AML)	Phase I	Phase II
	CYNK-001 (cryopreserved)	Glioblastoma Multiforme (GBM)	Phase I/IIa	Phase II
Genetically Modified Natural Killer Cell	**CYNK-101 + mAb**	HER2+ Gastric Cancer	IND Submission	Phase I/IIa → Phase II
CAR-T	**CyCART-19**	B-Cell Malignancies	IND Submission	Phase I → Phase II
Placental Mesenchymal-like Stromal Cell	**APPL-001**	Crohn's Disease	IND Submission	Phase I/IIa

2 Upcoming IND Submissions (2021E) & 5 Clinical Trials by end of 2021

Program Milestones

CYNK-001
- 2H21: Dose Selection & Initiation of Expansion Cohorts (AML)
- 2H21: Establish Phase II Dose (GBM)

CYNK-101
- 2H21: IND Submission
- 2H21: Phase I/IIa Study Start

CyCART-19
- 2H21: IND Submission Expected
- 1H22: Phase I Study Start

APPL-001
- 1H22: Phase I/IIa Study Start

STEMNESS: The Placental Advantage

At the core of Celularity's approach is the innate stemness of its starting material

Greatest Proliferative Potential and Sustained Activity:

Placenta-derived pluripotent stem cells have the highest natural ability to replicate while maintaining their activity, which could overcome the challenge of cell exhaustion.

Extended Persistence:

As nature's universal donor tissues, placental-derived pluripotent stem cells can be administered off-the-shelf with little or no modification and potentially persist longer in patients through their ability to avoid immune detection.

Flexible Engineering:

By starting with cells with high levels of innate stemness, Celularity has the opportunity for extensive genetic modifications focused on improving and directing the activity of its cellular therapies.

Superior Scalability and Economics:

Ethically sourced and screened, a single placenta can produce up to 100,000 doses of therapies through a manufacturing process that is highly efficient, modular and reproducible.

Greater T Stem Cell Memory Characteristics

Stem Cell Memory = Greatest Proliferative Potential, Persistence and Survival Benefit



	Marker	Naïve	Stem Cell Memory	Central Memory	Effector Memory
Phenotype	CD45RA	+	+	-	+/-
	CD27	+++	+++	++	+/-
	CCR7	+++	+++	++	-
	CD28	++	+++	+++	+/-
Function	Telomere	+++	+++	++	+
	Self-renewal	+	+++	++	+
	IFN-γ	-	+	++	+++
	IL-2	-	++	+++	+/-
	Cytotoxicity	-	+/-	+	+++

Adopted from Gattinoni *et al.* Nature Reviews Cancer 2012





Placental T cells consist mostly of T stem cell memory (Tscm) cells (stemness)

High proportion Tscm cells remain in CyCART-19 post expansion

Enhanced Efficacy & Persistence, Prolonged Immune Attack upon Tumor Rechallenge







- CyCART-19 demonstrates **significantly reduced tumor burden and survival benefit** compared to adult blood-derived CD19 CAR-T cells
- CyCART-19 **eliminated tumor** and resulted in **100% survival** out to **120 days**
- CyCART-19 "**memory" characteristics demonstrated** via:
  - **Extended survival out to 215 days** upon tumor re-challenge on Day 122
  - **Differentiated persistence** at end of study to elicit **prolonged antitumor** activities

Source: Celularity Data

Persistence, Maturation and Proliferation with Absence of Allo-HLA Antibodies

PNK-007 demonstrated **persistence up to 28 days** (mean=11days)



Persistent PNK-007 cells **matured and proliferated**



No detectable exhaustion on PNK-007 cells



PNK-007 **demonstrated effector function** post infusion



Absence of allo-HLA antibodies in all subjects



Source: AACR 2019 poster: Immune monitoring of CYNK-001, an allogeneic, off the shelf NK cell in a Phase I study of acute myeloid leukemia", Celularity data; *CYNK-001 is a comparable cryopreserved formulation of PNK-007, the product used in this study

CYNK-001
AML & GBM

CYNK-001(unmodified NK cellular therapy)
Overview

RATIONALE

- NK cells are natural immune cells that eradicate both cancer and virus-infected cells
  - Key mediators of antibody-dependent cellular cytotoxicity (ADCC)
- Placental-derived NK cells exhibit:
  - distinct, maturation and activation states
  - an immature phenotype
  - longer telomere length in comparison to PB NK cells, which suggests **high in-vivo proliferation and persistence**

KEY HIGHLIGHTS

CYNK-001 (unmodified NK cellular therapy)

- Preclinical data support anticancer activity against a range of hematological malignancies and solid tumors.
- Phase 1 study in R/R AML showed early signs of clinical benefit and a positive safety profile

CLINICAL PLAN

- Dose Selection & Initiation of Expansion Cohorts (AML) in 2H 2021
- Phase 1 study in adults with Recurrent Glioblastoma Multiforme
- Establish Phase II Dose (GBM) in 2H 2021

		NK CELL THERAPIES	
	Cell Therapy Technology Scorecard	**ADULT DONOR DERIVED**	**CELULARITY CYNK-001 & CYNK-101**
MANUFACTURING COMPLEXITY	**Source Procurement** Non-invasive Collection / Reliable Procurement	✓	✓
	Lower COGs Standardized, Scalable Manufacturing	✓	✓
	Starting Material Consistent Quality and Phenotype	✓	✓+
	Ability to Readily Expand While Maintaining a Less Differentiated Phenotype	✗	✓
	“Off-the-Shelf” Treatment	✓	✓+
	Ability to Re-dose Patients (if Necessary)	✗	✓+

PNK-007-AML-001 FIRST-IN-HUMAN STUDY

Phase I Study in Relapsed / Refractory Acute Myeloid Leukemia Showed Early Signs of Clinical Benefit

PHASE I RESULTS

- PNK-007 well tolerated in a heavily pre-treated AML patient population
  - **11** r/r AML patients enrolled, **10** treated with single dose of PNK-007, **no DLTs[1], no GvHD, no detectable HLA allo-antibody**
  - **8** of **10** patients were efficacy evaluable; the other **2** patients were not due to inadequate bone marrow (BM) for evaluation
    - 2 patients, both treated at the highest dose, had evidence of clinical benefit
      - **CRp[2] at Day 21**
      - **MLFS[3] at Day 14**

PHASE I DESIGN

- Dose escalation study
- Conditioning with cyclophosphamide and fludarabine
  - Fludarabine 25 mg/m2 x 5 days start day -6
  - Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (omit Day -4 if within 4 months of prior transplant)
- PNK-007 administered IV followed by up to 6 rhIL-2 injections
  - rhIL-2 at 6 million units subcutaneously beginning Day 0, every other day for 6 total doses

Note: NCT02781467. **[1] DLT: Dose Limiting Toxicity; [2] CRp: Complete Remission with incomplete platelet recovery; [3] MLFS: Morphologic Leukemia Free State**

CYNK001-AML-001 (MRD+/RELAPSED REFRACTORY AML)

Phase 1 Study Schema – In Progress



** CYNK-given on Days 0, 7 &14*
FOR Cohorts with IL-2 – Dose 6M IU on Days 0,2,4,7,9,11 & 14

CYNK001-GBM-002 (GLIOBLASTOMA PROGRAM)

Planned Phase 1 Dose Escalation / Phase 2 Proof of Concept



Phase 1 Dose Escalation

- N = ~ 21 patients
- North American sites (~5 sites)
- **Primary Endpoints**: Safety, Feasibility and Tolerability (42 Day DLT period)
- **Secondary Endpoints:** Progression Free Survival

Phase 2 Proof of Concept

- N = ~ 45 patients (80% Power - Target 35% 6-month PFS)
- North American sites (5 - 10 sites)
- **Primary Endpoints**: Overall Survival
- **Secondary Endpoints:** PFS, ORR post resection
- **Exploratory Endpoints:** NK cell persistence and trafficking

CYNK-101

HER2+ Advanced Esophageal / Gastric Adenocarcinoma

CYNK-101 IN HER2+ GASTRIC CANCER

Overview

RATIONALE

- Engineering CYNK cells with high affinity and cleavage resistant (CD16VP) expected to improve affinity for IgG1 therapeutic antibodies, resist activation induced cleavage and improve overall ADCC potential

KEY HIGHLIGHTS

- CYNK-101 adds “punching power” to the CYNK-001 platform via genetic modification
- When combined with Trastuzumab demonstrates ADCC activity against HER2+ Gastric Cancer cells
  - Joint impact of modified NK cells + mAb shows improved immunologic response with added NK cell killing

OPPORTUNITIES

- Enable combination therapy with ADCC mediating therapeutic mAb therapies
- Augment CYNK clinical program with added “punching power” of Genetic Modification

CLINICAL PLAN

- 2H21: IND Submission
- 2H21: Phase I/IIa Trial Start
- 1H22: Phase II Study Start





CYNK-101 DEMONSTRATES EFFECTIVE ANTITUMOR ACTIVITY

Against Gastric Cancer Cell Lines in Conjunction with Anti-HER2 Monoclonal Antibody

RESULTS

- Significant ADCC activity of CYNK-101 in combination with Trastuzumab against both gastric cancer cell lines was shown at E:T ratio of 2:1 over 24h in comparison with that of CYNK Non-Transduced (NT) or IgG control

CONCLUSION

- Demonstrated ADCC activity of CYNK-101 in combination with Trastuzumab against HER2+ gastric cancer cells
  - HER2+ Gastric demonstrated to be an immunologically susceptible tumor type with evidence of strong NK cell infiltration





CYNK-101 PROVIDES A BACKBONE FOR COMBINATION THERAPIES

Enhanced ADCC with Multiple Antibodies Forms the Basis of Combination Therapy



- Improved ADCC response observed from CYNK-101 compared to unmodified CYNK cells against lymphoma cell lines in combination with: Rituximab, Daratumumab and Elotuzumab antibodies
- IND-enabling studies on-going to evaluate CYNK-101 + mAbs in subcutaneous and orthotopic tumor models

CYNK101-HER2-001 (HER2+ GASTRIC/GEJ CANCER)

Planned Phase 1 - Dose Escalation / Phase 2a Expansion/Proof of Concept



Phase 1: Dose Escalation (n = up to 15 patients)

- **Primary Endpoints**: Determine safety and maximum tolerated dose
- **Secondary Endpoints**: Various Efficacy measures

Dosing Cohorts

CYNK101 Re-Indcution Dosing	CYNK101 Maintenance Dosing
Cohort -1: 1.8 x 10^9 cells	Cohort -1: 1.8 x 10^9 cells
Cohort 1: 3.6 x 10^9 cells	Cohort 1: 3.6 x 10^9 cells
Cohort 2: 7.2 x 10^9 cells	Cohort 2: 3.6 x 10^9 cells

Phase 2a: Expansion/Proof of Concept (n = ~40 patients)

- **Primary Endpoints**: ORR (CR+PR) (>65%-80%)
- **Secondary Endpoints**: (For patients that are CR, PR and SD)
  - Landmark PFS at 6 months & 12 months (CR, PR and SD)
  - Duration of Response (CR and PR)
  - Incidence of response conversion (PR and SD)
  - ORR for patients after initial induction are PD
  - Safety
- **Maintenance Dosing**
  - Patients in CR after CYNK-101 to dose an additional 2 cycles of NK cells combination
  - Patients in PR/SD after CYNK-101 to dose until CR or Progression
  - Patients in PD after CYNK-101 to discontinue to from study

CyCART-19
B-Cell Malignancies

CyCART-19 OVERVIEW

Celularity Approach and Advantages

RATIONALE

- Rationale for greater stemness, expandability, persistence
- Abundant renewable starting cell source for allogeneic therapies
- Potential for improved safety profile due to immunological naivety

KEY HIGHLIGHTS

- Celularity has established a robust process to obtain placental T naive/scm population as source materials to produce off-the-shelf, highly scalable CyCART-19 cells
- CyCART-19 demonstrates stem cell memory characteristics as evidenced by greater in vivo persistence and durable antitumor activity in preclinical models
- Strong pre-clinical evidence of anti-tumor activity
  - CyCART-19 cells outperform adult blood-derived CART cells by significantly greater persistence and longer survival in preclinical studies
- Early data suggesting no signs of GvHD
- Note: If Phase 1 successful, Celularity plans to pursue a Phase 2 basket trial across major B-cell malignancies (subject to FDA discussions)

CLINICAL PLAN

- 2H21: IND Submission Expected
- 2H21: Phase I Study Start
- 1H22: Phase II Study Start

		CAR-T THERAPIES		
	Cell Therapy Technology Scorecard	**AUTOLOGOUS**	**OTHER ALLOGENEIC**	**CELULARITY CyCART-19**
MANUFACTURING COMPLEXITY	**Source Procurement** Non-invasive Collection / Reliable Procurement	✗	✗	✓
	Lower COGs Standardized, Scalable Manufacturing	✗	✓	✓
	Starting Material Consistent Quality and Phenotype	✗	✗	✓+
	Ability to Readily Expand While Maintaining a Less Differentiated Phenotype	✗	✗	✓
	“Off-the-Shelf” Treatment	✗	✓	✓+
	Ability to Re-dose Patients (if Necessary)	✗	✓	✓+

CYCART19-BCM-001 (RELAPSED/REFRACTORY B-CELL MALIGNANCIES)

Planned Phase 1 Dose Escalation / Phase 2 Registrational

Phase 1
Safety and Dose Finding

Screening & Enrollment:

R/R CD19+ B-cell malignancies

Lymphodepletion:
CY 900 mg/m^2
Flu 30 mg/m^2
Mesna
Days -5, -4, -3

(Days -2, -1: no treatment)

Dose Level 1:
40 x10^6 cells
N=3

Dose Level 2:
120 x10^6 cells
N=3

Dose Level 3:
360 x10^6 cells
N=3

Dose Level 2 De-Escalation:
80 x10^6 cells
N=3

Dose Level 3 De-Escalation:
240 x10^6 cells
N=3

Phase 2:
Potential Registrational Cohorts

Cohort A: High Grade NHL
CD-19 targeted therapy naïve (n= ~66)

- DLBCL
- High Grade B-Cell lymphoma
- Primary mediastinal B-Cell lymphoma
- Transformed follicular lymphoma
- Mantle cell
- Burkitt lymphoma/leukemia
- Any B-Cell malignancy with Secondary CNS involvement

Cohort B: Low Grade NHL
CD-19 targeted therapy naïve (n= ~66)

- Follicular
- Marginal Cell
- CLL/SLL
- Waldenström's macroglobulinemia
- Any other low grade NHL subtypes

Cohort C: Any Grade NHL
CD-19 targeted therapy exposed
(n= ~66)

Cohort D: Primary Central Nervous System Lymphoma
(n= ~74)

IMUGENE COLLABORATION

Exclusive Strategic Partnership Combining CD19 Oncolytic Virus + CyCART-19 in Solid Tumors

- **Based on Dr. Yuman Fong's oncolytic virus technology from City of Hope**
- **OnCARlytics infects tumor cells → replicates and produces CF33-CD19 on the tumor cell surface**
  - Enables CD19 CAR-T therapy – CyCART-19 to recognize 'flags' on tumor surface
  - **Potential for CyCART to target solid tumors**





OnCARlytics Mechanism of Action:

Degenerative and Autoimmune Diseases

APPL-001 OVERVIEW

Celularity Approach and Advantages

RATIONALE

- Immune-modulatory properties of mesenchymal-like adherent stromal cells (ASCs) have the potential to alleviate autoimmunity and possess anti-inflammatory activity
- Off-the-shelf potential
  - ASCs are immune-privileged due to relatively low-level MHC class I and II protein expression

KEY HIGHLIGHTS

- Clinical evidence supporting ASCs potential applications
  - 1st generation ASCs demonstrate signs of clinical activity in Crohn's Disease, Diabetic Foot Ulcers and Diabetic Peripheral Neuropathy
  - Well-tolerated and no SAE's at therapeutic dose
- Placental-derived ASCs (APPL) are potentially more immune privileged due to their fetal origin
- Celularity is developing the next generation of ASCs with APPL-001, a genetically modified placental-derived ASC, for the treatment of Crohn's Disease
  - Engineered Tissue factor (TF) Knockout (KO) is designed to reduce potential toxicities and lower the risk of adverse effects.
- One placenta can yield more than 100,000 Doses.

CLINICAL PLAN

- Crohn's Disease
  - 1H22: IND Submission Expected
  - 1H22: Phase I/IIa Study Start

NEWLY DEVELOPED APPL PROGRAM

Leveraging Legacy Placental Mesenchymal-like Stromal Cell Studies to Expand to Degenerative Diseases

IV Formulation

50+ patients dosed in **multiple Crohn's Disease studies**

- Clinical response rates were significantly higher in IV Formulation treatment groups compared with the placebo group
- Response rates were 43% points in the treatment group vs 0% in the placebo group on Day 365
- Well-tolerated, no SAEs at therapeutic dose

IM Formulation

140+ patients dosed in **Diabetic Foot Ulcer (DFU) and Diabetic Peripheral Neuropathy Ph II studies**

- IM Formulation has systemic microvascular/neovascularization effects
- Enhanced healing of diabetic foot ulcers compared to placebo
- Improvement of retinopathy
- Well-tolerated, no SAEs at therapeutic dose







Source: Celularity Data

NEWLY DEVELOPED APPL PROGRAM

Leveraging PDA Cells and Develop New APPL Candidate

Genetically Modified APPL with Greater Safety Profile

- Tissue factor (TF) Knockout (KO) in APPL using CRISPR/Cas9 to reduce potential safety risk associated with TF
- Identified two of four CRISPR guide RNAs showing >95% high KO efficiency
- Demonstrated sustained TF KO throughout culture expansion
- APPL-TFKO cells significantly reduced TF activity
- TF KO showed no effect on cell proliferation and viability

Novel Media and Culture Method Established to Develop APPL with Greater Potency

- Demonstrate immune modulation and regenerative functionality
- New IP opportunities in process and product composition



Source: Celularity Data

Next Steps:

- Clinical Program Milestones

NEAR-TERM MILESTONES

To Achieve the Next Advance in Placenta-based Cell Therapy

Achievements to Date

April 2020:	Received FDA Safe to proceed on IND for CYNK-001 in COVID-19
September 2020:	Completion of Facility at Florham Park
January 2021:	Announce merger with GXGX Acquisition Corp.
	Completed concurrent $80m PIPE financing
March 2021:	Received Fast Track Designation by the FDA for CYNK-001 in recurrent GBM
April 2021:	Received Orphan Drug Designation by the FDA for CYNK-001 in malignant gliomas
July 2021:	Complete public listing on NASDAQ (CELU)

Key Near-Term Development Milestones

CYNK-001

- 2H21: Establish Phase 2 Dose (GBM)
- 2H21: Dose Selection & Initiation of Expansion Cohorts (AML)

CYNK-101

- 2H21: IND Submission
- 2H21: Phase I/IIa Study Start

CyCART-19

- 2H21: IND Submission
- 1H22: Phase I Study Start

APPL-001

- 1H22: Phase I/IIa Study Start

Appendix

Additional Detail

CELULARITY IMPACT™ PLATFORM

Broad IP Protection Across All Lead Programs



CELULARITY IMPACT™ PLATFORM

The Placenta as a Renewable Allogeneic Source, with Purpose-Built Commercial Scale Manufacturing



CELULARITY PLACENTAL CAR-T (CyCART)

Solving the Downside of Autologous CAR-T Therapies

AUTOLOGOUS CAR-T THERAPY		*ALLOGENEIC PLACENTAL CAR-T*
Status Quo	**Downside**	**Celularity's Scalable Solution**
➢ All CAR T-cell therapies on the market and most (~75%) of clinical assets are autologous	▪ Complex, high COGS manufacturing and *one-batch, one-patient* supply chain	✓ No apheresis capacity constraints ✓ High volume manufacturing ✓ On-demand, off-the-shelf cryopreserved packaged product
➢ Peripheral blood-derived T-cell is the immune cell 'vehicle' used to express a CAR	▪ Multiple rounds of lymphocyte-depleting therapies cause inconsistent apheresis cell recovery in relapsed or refractory patients	✓ Placentas provide a profuse, renewable source of healthy, ready to use lymphocytes ✓ Placental T-Cells containing abundance of stem cell memory conferring greater expansion and persistence potential
		UNIQUE ADVANTAGES OF PLACENTAL-DERIVED CELLS
➢ "Patient as their own donor" automatically makes the patient part of the supply chain	▪ Therapeutic outcomes affected by c*ollection-manufacturing-release-administration* timeframe "Long vein-to-vein time"	✓ Dynamic & flexible supply chain ✓ Patient-responsive, not patient-dependent ✓ Simplified logistics, ability to pre-position cryopreserved product at treatment sites

CELULARITY PLACENTAL CAR-T (CyCART)

Providing Upside to Adult-donor Allogeneic CAR-T Therapies

ALLOGENEIC CAR-T THERAPY		*ALLOGENEIC PLACENTAL CAR-T*
Status Quo	**Downside**	**Celularity's Scalable Solution**
➢ Requires selection, screening & testing T cells from healthy adult donors e.g. donor bone marrow	▪ Complex logistics, multistep manufacturing process to source, limited scalability, improved speed vs. autologous but still measured in days	✓ No apheresis capacity constraints ✓ High volume manufacturing ✓ On-demand, off-the-shelf cryopreserved packaged product
➢ High cost of treatment inherent of engineered T cell therapy	▪ Requires separate engineering for each new therapeutic candidate	✓ Placentas provide an abundant, renewable source of healthy, ready to use lymphocytes ✓ Placental T-Cells containing abundance of stem cell memory conferring greater expansion and persistence potential
➢ Adult donor ≠ universal donor	▪ Potential safety complications observed from graft versus host disease (GvHD), as well as CRS and cerebral edema	✓ Dynamic & flexible supply chain ✓ Patient-responsive, not patient-dependent ✓ Simplified logistics, ability to pre-position cryopreserved product at treatment sites

UNIQUE ADVANTAGES OF PLACENTAL-DERIVED CELLS

CyCART-19 CELLS DO NOT INDUCE XENOGENEIC GvHD IN VIVO

Efficient TCR Knockout as Risk Mitigation









- **Placental T (P-T) cells do not induce xenogeneic GvHD in vivo**
  - Evidenced by **100% survival**, **no weight loss**, no increase in detection of any human CD3+ T cells in P-T treated mice
  - PBMC-treated mice exhibited significant weight loss, death of all mice, and increase of detection of human CD3+ T cells at Day 28
- Celularity includes CRISPR-mediated TRAC KO in its process as a risk mitigation strategy to prevent GvHD
  - **97-99% TRAC KO efficiency achieved in CyCART-19 cells**

Source: Celularity Data

CELULARITY PLACENTAL NK CELLS

Providing Upside to both Adult-donor NK Cells

ADULT DONOR NK CELL THERAPY		*ALLOGENEIC PLACENTAL NK*
Peripheral Blood NK	**iPSC NK**	**Celularity's Scalable Solution**
➢ Apheresis of peripheral blood from healthy donor / patient ➢ Requires voluntary donor	▪ De-differentiated adult fibroblasts ▪ Additional processing required	✓ No apheresis capacity constraints ✓ High volume manufacturing ✓ On-demand, off-the-shelf cryopreserved packaged product
➢ Cytokine activation without expansion or direct expansion on feeder cell platform	▪ Two-stage differentiation: – First from iPSC's to iCD34 cells, and then to NK cells ▪ Expression of multiple de-differentiation genes higher risk of insertional mutagenesis	✓ Feeder cell-free, cytokine cocktail-based NK cell expansion and differentiation ✓ No prior exposure to physiological or environmental factors; no exhaustion
➢ Heterogeneous NK cells with high expression of both NK cell activating receptors and inhibitory receptors (KIRs) ➢ Potential for fratricide exists with CD38 mAb	▪ NK cells with high expression of both NK cell activation and inhibitory receptors (KIRs) ▪ Potential for fratricide necessitated knock out of CD38 when combined with CD38 mAb	✓ Heterogeneous NK cells with high expression of natural cytotoxicity receptors (NCRs) with low expression of inhibitory receptors (KIRs) ✓ No fratricide observed in combination with CD38 targeted approaches

APPL CROHN'S DISEASE (CD)

Study Design

Study Design: Randomized, double-blind, Placebo-controlled study in adults with 5 doses of 1/4th unit APPL (~ 37 million cells) over 8 weeks vs. Humira treatment.

Study Population: Moderate-to-Severe CD (CDAI score: 220-450) who are refractory to Corticosteroids

Primary objective: To assess the clinical efficacy by measuring response/remission rates during the induction phase as well as to explore durability of response during the maintenance phase in subjects with moderate to severe CD. Subjects shall be re-treated if a flare is developed during the 1-year.

Secondary Objective: The secondary objectives of this study are to assess clinical improvement by endoscopic measurements and quality of life assessments.

Primary Endpoint: To assess clinical efficacy, the modified Crohn's Disease Activity Index (CDAI) scoring system will be used to measure the following:

- Clinical Remission: Reduction of CDAI score to less than 150 points 4-6 weeks
- Clinical Remission: Reduction of CDAI score to less than 150 points 1-year

Secondary Endpoints:

- Clinical Response Rate: Reduction in CDAI score by 100 points to the baseline at 1-year
- Evaluation of mucosal healing as measured by Simple Endoscopic Score for Crohn's Disease (SES-CD) at week 4-6 and 1-year
- Patient-reported outcome of quality of life as measured by Inflammatory Bowel Disease Questionnaire (IBDQ)

Sample Size: 162 subjects in each arm (80% power and 10% drop out) involving APPL versus Humira with NI margin of 12%

Timeline Estimate:

- IND: 1H 2022

MANUFACTURING PROCESS

Celularity Purpose-built Commercial Scale150,000 sq. ft. Manufacturing Facility

Network of Longstanding Partnerships

- Birthing Centers
- Obstetricians
- Academic Hospitals
  - Controllable and scalable on-demand birthing material
  - Supports multiple products/programs

Controlled Courier System

- Procurement Kits
- Temperature tracking
- Unique barcoding/labeling
- Traceability from birthing center to Celularity through manufacturing & distribution

Collection & Documentation of Donor Information

- Qualified donors/Donor eligibility
- Informed consent
- Detailed maternal and family health questionnaire
- Completed delivery information
- Comprehensive data set on donor and cell source



Cell Isolation and Selection

- Proprietary perfusion methodology
- Removal of vascular/ circulatory blood
- Cell suspension/separation
- Cell selection/sorting for hematopoietic, progenitor, and T-cells.
- Cryopreserved donor stock



Cell Manufacturing

- Controllable and flexible manufacturing
- Cell seeding, expansion and differentiation
- Cell harvesting & formulation
- Use of automation (i.e., bioreactors, etc.)
- Highly scalable

Tissue Manufacturing

- Multiple commercial products with (30+ SKUs)
- Multiple suite allocation allows for rapid increase in product manufacturing
- Multiple shift manufacturing
- In house packaging capability
- Ambient product storage
- Long product shelf life/expiry

Product Cryopreservation

- In-process cooling/cryopreservation of drug product
- In-house cryostorage facility with 24/7 monitoring
- Long term storage readiness
- Cold-chain logistics and distribution expertise
- Cold-chain monitoring and traceability



Delivery to Patients



ALLOGENEIC PLACENTAL PLURIPOTENT CELLS: SCALABLE & OFF-THE-SHELF

Clinical Stage





Target Product Profile

- Culture expanded, undifferentiated Mesenchymal-like Stromal Cells (MSCs)
- Composition: CD34-, CD10+, CD105+, and CD200+
- MOA: Immune-modulatory, anti-inflammatory, pro-angiogenic, cytoprotective, pro-regenerative
- Targets: auto-immune disorder, inflammation, wound healing, tissue repair

One Placenta > 100,000 Doses

Source: Celularity Data

AML: PRE-CLINICAL DATA

Evidence of Significant Leukemia Killing

CML, AML, MM IN VITRO KILLING



PNK-007 demonstrates robust killing (cytolytic) against CML, AML, MM cell lines and primary AML samples

IFN-G PRODUCTION



PNK-007 activation releases high concentration of IFN-g, favoring Th1 responses

PRIMARY AML KILLING



PNK-007 exerted up to 60% specific lysis against primary AML samples at an Effector: Target (E:T) ratio of 3:1